Codexis, Inc. (CDXS)
Nasdaq · Healthcare · Biotechnology
$1.39+2.21%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $152M
- 52-week range
- $0.96 – $2.98
- 52-week change
- −49.44%
- EPS (trailing)
- −$0.33
- Analyst rating
- 1.6 Buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $70.4M (+18.61%)
- Net income
- −$44.0M
- Operating margin
- −59.3%
- Diluted EPS
- −$0.50
- Free cash flow
- −$23.9M
From the company’s annual report on SEC EDGAR.
About Codexis, Inc.
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Headquarters: Redwood City, United States · 146 employees · codexis.com